The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-07 and is reviewed periodically as new material appears.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
== Pathophysiology == People with OI are either born with defective connective tissue, born without the ability to make it in sufficient quantities, or, in the rarest genetic types, born with deficiencies in other aspects of bone formation such as chaperone proteins, the Wnt signaling pathway, the BRIL protein, et cetera. In type I the collagen's structure itself is normal, it is just its quantity that is low. Types II, III and IV are usually, but not always, related to a deficiency of type I collagen. One possible deficiency arises from an amino acid substitution of glycine to a bulkier amino acid, such as alanine, in the collagen protein's triple helix structure. The larger amino acid side-chains lead to steric effects that creates a bulge in the collagen complex, which in turn influences both the molecular nanomechanics and the interaction between molecules, which are both compromised. Depending on both the location of the substitution and the amino acid being used instead, different effects are seen which account for the type diversity in OI despite the same two collagen genes being responsible for most cases. Replacements of glycine with serine or cysteine are seen less often in fatal type II OI, while replacements with valine, aspartic acid, glutamic acid, or arginine are seen more often. At a larger scale, the relationship between the collagen fibrils and hydroxyapatite crystals to form bone is altered, causing brittleness.
Space Invaders, originally released for arcades in 1978, became a killer app when it was ported to the Atari VCS console in 1980, quadrupling sales of the three-year-old console. Star Raiders, released in 1980, was the first killer app computer game. BYTE named it the single most important reason for sales of Atari 400 and 800 computers. Another was Eastern Front (1941), released in 1981. In 1996, Computer Gaming World wrote that Wizardry: Proving Grounds of the Mad Overlord (1981) "sent AD&D fans scrambling to buy Apple IIs". The Famicom home port of Xevious is considered the console's first killer app, which caused system sales to jump by nearly 2 million units. Computer Gaming World stated that The Legend of Zelda on the Nintendo Entertainment System, Phantasy Star II on the Sega Genesis, and Far East of Eden for the NEC TurboGrafx-16 were killer apps for their consoles. The Super Mario, Final Fantasy, and Dragon Quest series were killer apps for Nintendo's Famicom and Super Famicom consoles in Japan. John Madden Football's popularity in 1990 helped the Genesis gain market share against the Super NES in North America. Sonic the Hedgehog, released in 1991, was hailed as a killer app as it revived sales of the three-year-old Genesis. Mortal Kombat helped pushed the sales of the Genesis due to being uncensored unlike the Nintendo version. Streets of Rage became a system seller for the Mega Drive/Genesis in the UK. Street Fighter II, originally released for arcades in 1991, became a system-seller for the Super NES when it was ported to the platform in 1992.
== Names == The initial strikes on Iran were codenamed Operation Epic Fury by the United States government, and Operation Roaring Lion by the Israeli government, in line with their codename of Operation Rising Lion for their strikes on Iran during the Twelve-Day War in June 2025. Iran codenamed its response Operation True Promise IV (Persian: عملیات وعده صادق ۴, romanized: Amaliyat-e Va'deh-ye Sadegh 4). American media outlets have generally referred to the conflict as the Iran war. The war has also been referred to by some outlets as the "Third Gulf War" (Gulf War III), following the Gulf War (1990–1991), and the Iraq War/Second Gulf War (Gulf War II) (2003–2011). Iranian state media has referred to the conflict as the "Third Imposed War", with the Iran–Iraq War (1980–1988) and the Twelve-Day War respectively as the "First" and "Second". Due to the war starting during the month of Ramadan, it has sometimes been called the "Ramadan War". The American codename morphed into "Operation Epstein Fury", which became popularized across many social media platforms and also drew criticism from the ADL.
Peña has stated his intention for his cabinet to be composed entirely or mostly of members of the Colorado Party. The president, vice president, and the other members of the cabinet took office on 15 August 2023.
Gorlin's sign is a medical term that indicates the ability in humans to touch the tip of the nose with the tongue. Approximately ten percent of the general population can perform this act, but fifty percent of people with Ehlers–Danlos syndrome (an inherited connective tissue disorder) have the ability. The sign is named after pathologist Robert J. Gorlin, who described it in twentieth century medical literature. Gorlin's sign should not be confused with Gorlin syndrome, a serious inherited medical condition also named after the same pathologist.
Sources: en.wikipedia.org
can be important is the calculation of energy loss in sound and shock waves, described by Stokes' law of sound attenuation, since these phenomena involve rapid expansions and compressions. The defining equations for viscosity are not fundamental laws of nature, so their usefulness, as well as methods for measuring or calculating the viscosity, must be established using separate means. A potential issue is that viscosity depends, in principle, on the full microscopic state of the fluid, which encompasses the positions and momenta of every particle in the system. Such highly detailed information is typically not available in realistic systems. However, under certain conditions most of this information can be shown to be negligible. In particular, for Newtonian fluids near equilibrium and far from boundaries (bulk state), the viscosity depends only space- and time-dependent macroscopic fields (such as temperature and density) defining local equilibrium. Nevertheless, viscosity may still carry a non-negligible dependence on several system properties, such as temperature, pressure, and the amplitude and frequency of any external forcing. Therefore, precision measurements of viscosity are only defined with respect to a specific fluid state. To standardize comparisons among experiments and theoretical models, viscosity data is sometimes extrapolated to ideal limiting cases, such as the zero shear limit, or (for gases) the zero density limit.
In biochemistry, non-coded or non-proteinogenic amino acids are distinct from the 22 proteinogenic amino acids (21 in eukaryotes), which are naturally encoded in the genome of organisms for the assembly of proteins. However, over 140 non-proteinogenic amino acids occur naturally in proteins (but not included in the genetic code) and thousands more may occur in nature or be synthesized in the laboratory. Chemically synthesized amino acids are often referred to as unnatural or non-canonical amino acids. Unnatural amino acids can be synthetically prepared from their native analogs via modifications such as amine alkylation, side chain substitution, structural bond extension cyclization, and isosteric replacements within the amino acid backbone. Many non-proteinogenic amino acids are important:
{\displaystyle {\begin{aligned}R_{*}&={\frac {\varepsilon }{D}}\cdot \mathrm {Re} {\sqrt {f_{\mathrm {D} }}}\cdot {\frac {1}{\sqrt {8}}}\\&={\frac {1}{2}}{\frac {\sqrt {g}}{\nu }}\varepsilon {\sqrt {S}}{\sqrt {D}}\end{aligned}}}
The first variety, a cracker similar to a cross between an unsalted saltine and hardtack, Crown Pilot Crackers. It was a popular item in much of New England and was manufactured by Nabisco until it was discontinued in the first quarter of 2008. It was discontinued once before, in 1996, but a small uprising by its supporters brought it back in 1997. This variety comes in two sub-varieties, Flaky and Barge biscuits. The second is Hard Bread, a traditional hardtack, and is the principal ingredient in fish and brewis, a traditional Newfoundland and Labrador meal. The third variety is Sweet Bread, which is slightly softer than regular hardtack due to a higher sugar and shortening content, and is eaten as a snack food.
Sources: en.wikipedia.org
This article incorporates public domain material from The World Factbook (2025 ed.). CIA. (country: Honk Kong) Hong Kong from BBC News Key Development Forecasts for Hong Kong from International Futures Hong Kong in Transition (1995–2020) Archived 20 March 2025 at the Wayback Machine, an open access photographic archive of recent Hong Kong history Government
Bukele's popularity as mayor of San Salvador led some journalists to believe that he would run for president in 2019, but he denied that he would. He eventually expressed interest in running for president with the FMLN, but the party did not consider him as its vice-presidential nominee. He wrote on social media that the FMLN had purged him, and portrayed himself as an independent politician who rejected the country's political system. On 15 October 2017, Bukele announced his intention to run for president in 2019 and form a new political party. He announced the establishment of the Nuevas Ideas party on 25 October 2017 on social media, saying that Nuevas Ideas would seek to remove ARENA and the FMLN from power. During his presidential campaign, Bukele and a network of YouTubers, bloggers, and internet trolls attempted to discredit ARENA and the FMLN. Bukele tried to associate the two parties with the governments of previous presidents that were marred by corruption, using slogans such as "There's enough money when nobody steals" and "Return what was stolen". His campaign promises included the creation of an international commission to combat corruption, the development of a trans-national railroad and a new airport, job opportunities for Salvadorans, and reduced crime.
Half-Life is a series of first-person shooter games created and published by Valve. Since the release of the original Half-Life for Windows in 1998, several Half-Life projects have been canceled, including some developed by other studios. In 1999, Valve canceled a Half-Life port for Mac developed by Logicware. Half-Life: Hostile Takeover, an expansion pack for Half-Life developed by 2015, was cancelled in 2000. In 2001, Sierra, the publisher of the original Half-Life, canceled a port for Dreamcast after Sega announced its discontinuation. After releasing Half-Life 2: Episode Two in 2007, Valve struggled to settle on a direction for a new Half-Life game. Episode Three was canceled after Valve abandoned episodic development and began developing a new game engine, Source 2. Another Half-Life 2 episode, by Junction Point Studios, was canceled after Junction Point was acquired by Disney Interactive Studios. Valve moved the project to Arkane Studios, who developed it as Ravenholm, set in the town infested with zombies from Half-Life 2 (2004). Valve canceled it as they felt it was creatively restrained. Valve developed Half-Life 3 between 2013 and 2014, experimenting with procedurally generated levels, but canceled it as the Source 2 engine was still unfinished. A virtual reality (VR) game set on a time-travelling ship, Borealis, was canceled as the VR technology and tools were not complete. As of 2025, datamines and leaks suggested that a Half-Life game codenamed HLX was in development using Source 2.
Reconstructions of rainfall amount in the tropics in the geological past are mostly based on δ18O of speleothems or δD of biogenic lipids, both of which are thought of as proxies for the isotopic composition of precipitation.
The first decision of the Socialist government of José Luis Rodríguez Zapatero was to order the withdrawal of Spanish troops from Iraq, thus fulfilling what was promised during the electoral campaign, which was accompanied by a rapprochement with Germany and France. This allowed the negotiations of the Treaty of the European Constitution, which was signed in Rome in October 2004, to be unblocked. Zapatero hastened to call the ratification referendum held in February 2005, which obtained the approval of 75% of the voters but registered the highest abstention of all democracy. However, Rodríguez Zapatero was isolated internationally when the European Constitution project foundered and, above all, when Germany and France "reconciled" with the United States. Moreover, his proposal for the Alliance of Civilizations presented to the 2004 UN General Assembly as an alternative to President Bush's "war on terror" found little international backing. The Popular Party blamed its defeat in the elections on the "manipulation" of public opinion during the two days following the "11-M" attack by the PSOE and the related media. Thus, the PP implicitly questioned the legitimacy of the new government and in the sessions of the parliamentary commission that was formed to investigate the events the PP spokesmen led by Eduardo Zaplana, endorsed the 11-M conspiracy theory.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.